Myoglobin clearance with continuous veno-venous hemodialysis using high cutoff dialyzer versus continuous veno-venous hemodiafiltration using high-flux dialyzer: a prospective randomized controlled trial

Table 3 Safety endpoints

Variable	Control arm CVVHDF, n = 33	Intervention arm CVVHD-HCO, n = 35	p value
Clinical outcome
ICU length of stay (days)	11 (5.21)	13 (7.27)	0.543
ICU mortality	10 (30.3%)	22 (62.9%)	0.007
Hospital mortality	18 (54.5%)	24 (68.6%)	0.234
Mortality day 28	15 (45.5%)	21 (60%)	0.23
Mortality day 90	21 (65.6%)	25 (73.5%)	0.485
Adverse events			0.205
Hypocalcemia	1 (3%)	6 (17.1%)
Metabolic alkalosis	1 (3%)	0 (0%)
Citrate accumulation	0 (0%)	0 (0%)
Catheter malfunction	1 (3.3%)	1 (2.9%)
Severe adverse events			0.265
Treatment-associated life-threatening complication	0 (0%)	0 (0%)
Dead of any cause during intervention	2 (6.1%)	5 (14.3%)

Data presented as n (%). median [25th, 75th quantile]
ICU intensive care unit, CVVHDF continuous veno-venous hemodiafiltration, CVVHD-HCO continuous veno-venous hemodialysis using high cutoff filter